JP2020528059A - 悪性腫瘍を同定および診断するためならびに治療的抗腫瘍介入をモニターするための、９９ｍＴｃチルマノセプトおよび関連する分子構造の使用 - Google Patents

悪性腫瘍を同定および診断するためならびに治療的抗腫瘍介入をモニターするための、９９ｍＴｃチルマノセプトおよび関連する分子構造の使用 Download PDF

Info

Publication number
JP2020528059A
JP2020528059A JP2020502669A JP2020502669A JP2020528059A JP 2020528059 A JP2020528059 A JP 2020528059A JP 2020502669 A JP2020502669 A JP 2020502669A JP 2020502669 A JP2020502669 A JP 2020502669A JP 2020528059 A JP2020528059 A JP 2020528059A
Authority
JP
Japan
Prior art keywords
tumor
composition
imaging
dextran
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020502669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528059A5 (https=
Inventor
フレデリック・オー・コープ
ボニー・チャンドラー・アブルッツェッセ
デーヴィッド・アレン・ラルフ
アリソン・キスリング
Original Assignee
ナビディア・バイオファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナビディア・バイオファーマシューティカルズ，インコーポレーテッド filed Critical ナビディア・バイオファーマシューティカルズ，インコーポレーテッド
Publication of JP2020528059A publication Critical patent/JP2020528059A/ja
Publication of JP2020528059A5 publication Critical patent/JP2020528059A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
JP2020502669A 2017-07-21 2018-07-20 悪性腫瘍を同定および診断するためならびに治療的抗腫瘍介入をモニターするための、９９ｍＴｃチルマノセプトおよび関連する分子構造の使用 Pending JP2020528059A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762535752P 2017-07-21 2017-07-21
US62/535,752 2017-07-21
PCT/US2018/043176 WO2019018815A1 (en) 2017-07-21 2018-07-20 USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS

Publications (2)

Publication Number Publication Date
JP2020528059A true JP2020528059A (ja) 2020-09-17
JP2020528059A5 JP2020528059A5 (https=) 2021-08-26

Family

ID=65014640

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020502669A Pending JP2020528059A (ja) 2017-07-21 2018-07-20 悪性腫瘍を同定および診断するためならびに治療的抗腫瘍介入をモニターするための、９９ｍＴｃチルマノセプトおよび関連する分子構造の使用

Country Status (7)

Country Link
US (1) US20190022259A1 (https=)
EP (1) EP3655107A4 (https=)
JP (1) JP2020528059A (https=)
CN (1) CN111447955A (https=)
CA (1) CA3070494A1 (https=)
IL (1) IL272123A (https=)
WO (1) WO2019018815A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3127487A1 (en) * 2019-01-25 2020-07-30 Navidea Biopharmaceuticals, Inc. Compositions and methods for assessing macrophage mediated pathology
US20210052639A1 (en) * 2019-08-19 2021-02-25 Navidea Biopharmaceuticals, Inc. Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells
US20210145989A1 (en) * 2019-09-30 2021-05-20 Navidea Biopharmaceuticals, Inc. Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands
EP4076540A4 (en) * 2020-07-08 2024-02-21 Navidea Biopharmaceuticals, Inc. Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof
CA3192041A1 (en) * 2020-08-21 2022-02-24 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
EP4472643A1 (en) 2022-02-04 2024-12-11 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
US20230302041A1 (en) * 2022-03-25 2023-09-28 Navidea Biopharmaceuticals, Inc. Competitive Self-Blocking with Unlabeled Manocept Imaging Agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016527252A (ja) * 2013-07-22 2016-09-08 ナビディア・バイオファーマシューティカルズ，インコーポレーテッド Ｃｄ２０６発現細胞関連障害を診断および処置するための組成物、方法およびキット

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671256A (en) * 1984-05-25 1987-06-09 Lemelson Jerome H Medical scanning, monitoring and treatment system and method
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
JP2005226021A (ja) * 2004-02-16 2005-08-25 Nihon Medi Physics Co Ltd マンノース受容体親和性化合物
US20170202969A1 (en) * 2014-07-17 2017-07-20 Larry Schlesinger Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
CA2955438C (en) * 2014-07-17 2024-07-02 Ohio State Innovation Foundation DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR
WO2016011419A1 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
US10806803B2 (en) * 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
WO2016118188A1 (en) * 2015-01-21 2016-07-28 Navidea Biopharmaceuticals, Inc. Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells
WO2018067751A1 (en) * 2016-10-04 2018-04-12 Navidea Biopharmaceuticals, Inc. Compositions and methods for diagnosing and treating macrophage-related disorders using carbohydrate-based macromolecular carrier
MX2019004029A (es) * 2016-10-07 2019-09-27 Navidea Biopharmaceuticals Inc Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
EP3522899A4 (en) * 2016-10-07 2020-05-06 Navidea Biopharmaceuticals, Inc. Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016527252A (ja) * 2013-07-22 2016-09-08 ナビディア・バイオファーマシューティカルズ，インコーポレーテッド Ｃｄ２０６発現細胞関連障害を診断および処置するための組成物、方法およびキット

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"History of Changes for Study: NCT03029988", CLINICALTRIALS.GOV ARCHIVE [ONLINE], JPN6022028435, 18 July 2017 (2017-07-18), ISSN: 0005149566 *
AZAD, A. K.: "Mannose receptor (CD206)-mediated imaging in sentinel lymph node localization", CLINICAL AND TRANSLATIONAL IMAGING, vol. 3, JPN6022028434, 2015, pages 237 - 245, ISSN: 0005149565 *
CHENG, D. ET AL.: "Preparation and Evaluation of 99mTc-labeled anti-CD11b Antibody Targeting Inflammatory Microenvironm", CHEMICAL BIOLOGY & DRUG DESIGN, vol. 85, no. 6, JPN6023037037, 2015, pages 696 - 701, XP055822437, ISSN: 0005149567, DOI: 10.1111/cbdd.12459 *
UMEMURA, N. ET AL.: "Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages t", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 83, no. 5, JPN6023037039, 2008, pages 1136 - 1144, ISSN: 0005280397 *
シャンド・フランシス: "腫瘍関連マクロファージ—がんの微小環境を大きく左右する細胞", 医学のあゆみ, vol. 第259巻, 第5号, JPN6023004347, 2016, pages 480 - 485, ISSN: 0005149568 *
松本 岳, 戸井 雅和: "腫瘍関連マクロファージ(TAM)", SURGERY FRONTIER, vol. 第8巻, 第2号, JPN6023004349, 2001, pages 186 - 189, ISSN: 0005149569 *
柴田 昌彦 ほか: "myeloid-derived suppressor cells(骨髄由来免疫抑制細胞:MDSCs)の同定と機能解析", SURGERY FRONTIER, vol. 第20巻，第1号, JPN6023037038, 2013, pages 85 - 89, ISSN: 0005280398 *
菰原 義弘, 竹屋 元裕: "癌病巣におけるマクロファージの多様性と役割", 血管医学, vol. 第15巻, 第2号, JPN6023004350, 2014, pages 141 - 147, ISSN: 0005149570 *

Also Published As

Publication number Publication date
US20190022259A1 (en) 2019-01-24
CA3070494A1 (en) 2019-01-24
WO2019018815A1 (en) 2019-01-24
EP3655107A4 (en) 2021-04-28
IL272123A (en) 2020-03-31
EP3655107A1 (en) 2020-05-27
CN111447955A (zh) 2020-07-24

Similar Documents

Publication Publication Date Title
JP2020528059A (ja) 悪性腫瘍を同定および診断するためならびに治療的抗腫瘍介入をモニターするための、９９ｍＴｃチルマノセプトおよび関連する分子構造の使用
JP7066780B2 (ja) マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法
US11623007B2 (en) Long-lived gadolinium based tumor targeted imaging and therapy agents
CN101137398B (zh) 用于双重显像和放射化疗的缀合物：组合物、生产和应用
US20220062448A1 (en) Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
JP6607854B2 (ja) Ｃｄ２０６発現細胞関連障害を診断および処置するための組成物、方法およびキット
US20190021608A1 (en) CD206+ Macrophage-Specific Molecular Imaging Probe Compositions and Methods and the Noninvasive Quantification of Arterial Wall Macrophage Infiltration in Humans
US11186598B2 (en) Radioactive phospholipid metal chelates for cancer imaging and therapy
US20170209584A1 (en) Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
DE102010010666A1 (de) Diagnose und Therapie von Krebserkrankungen mittels Fettsäuren
US20170202969A1 (en) Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
JP6310567B2 (ja) アテローム動脈硬化映像化用組成物、及びそれを用いたアテローム動脈硬化の診断方法
JP2022500533A (ja) 腫瘍アシドーシス画像化のためのデュアルモダリティｕｐｓナノプローブ
JP2010517939A (ja) 細胞の検出のための化合物および方法
US20130302243A1 (en) Radiolabeled nanosystem, process for the preparation thereof and its use
US20250121100A1 (en) Composition and method for diagnostic imaging
Yang et al. Evaluation of Intratumoral Injection of Poly (d, l-lactide) Cisplatin Microspheres in Rats with Breast Tumors Using [131I] lodomisonidazole (IMISO)
Pares et al. European Association of Nuclear Medicine-30th Annual Meeting. Vienna, Austria-October 21-25, 2017

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210719

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240312